Cameroonian Startup Reimagines African Clinical Trials

From helping hospitals find life-saving blood to helping researchers test clinical trials before enrolling a single patient, Infiuss Health has undergone a remarkable evolution.

Founded and led by Cameroonian entrepreneur and CEO Melissa Bime, the company began as a digital blood-supply platform before expanding into clinical-research technology. Today, Infiuss builds AI-powered medical digital twins from real-world and historical data, allowing pharmaceutical companies, research sponsors and clinical teams to simulate how trial protocols could perform across thousands of virtual patients.

Its value proposition is to make clinical research faster, more representative and less dependent on costly trial-and-error. Through its Probe platform, researchers can evaluate protocol scenarios, forecast recruitment and dropout, identify suitable participants, collect consent and manage remote, hybrid or onsite studies.

Infiuss has built a registry of more than 21,000 willing research participants, while its current platform is designed to reduce required enrolment by up to 30%, accelerate design cycles tenfold and shorten decision timelines by four to six months. By connecting researchers with African patients historically underrepresented in global studies, the company is also helping improve the diversity and relevance of medical evidence.

Infiuss joined Y Combinator’s Summer 2021 cohort, secured investment from UM6P Ventures in 2022, and had expanded its clinical-trial recruitment services into six African countries by that year.

These milestones reflect Bime’s ability to reposition the company as healthcare needs and technology evolved—from supporting 23 Cameroonian hospitals through its original blood platform to developing infrastructure for decentralised trials and AI-assisted drug development. Her work earned her the 2018 Cartier Women’s Initiative Award for Sub-Saharan Africa and the $25,000 Grand Prize at the 2018 Anzisha Prize.